对于脉络膜新生血管形成(CNV)相关疾病而言,光动力疗法(PDT)已成为一种较成熟的治疗方法。其阻止了数以百万计的CNV患者视力的严重下降,但也不得不承认其固有的缺陷。随着抗新生血管药物研究的重大进展,PDT在治疗CNV疾病中的地位有所降低。然而,目前尚无任何一种疗法可以理想地治疗CNV疾病,因此必须客观评价PDT的有效性和安全性。合理选择适应证和治疗方案,PDT仍将是CNV疾病综合治疗中不可替代的有力手段之一。 Photodynamic therapy (PDT) has become a more mature treatment for diseases related to choroidal neovascularization (CNV). It prevents the severe vision loss of millions of CNV patients, but also has to admit its inherent flaws. With the significant advances in anti-angiogenic drug research, the status of PDT in the treatment of CNV diseases has been reduced. However, there is no one kind of therapy that can treat CNV disease ideally. Therefore, it is necessary to objectively evaluate the efficacy and safety of PDT. Reasonable choice of indications and treatment programs, PDT will remain CNV disease comprehensive treatment of irreplaceable one of the powerful tools.